ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (21)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Polzin, A.
Right arrow Articles by Lode, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Polzin, A.
Right arrow Articles by Lode, H.
Eur Respir J 2003; 21:939-943
Copyright ©ERS Journals Ltd 2003


Procalcitonin as a diagnostic tool in lower respiratory tract infections and tuberculosis

A. Polzin1, M. Pletz1, R. Erbes1, M. Raffenberg1, H. Mauch2, S. Wagner2, G. Arndt3 and H. Lode1

1 Dept of Chest and Infectious Diseases and 2 Institute for Microbiology, City Hospital Emil von Behring and 3 Institute for Biometrics and Data Processing, Dept of Veterinary Medicine, Free University of Berlin, Berlin, Germany

CORRESPONDENCE: H. Lode, City Hospital Emil von Behring, Free University of Berlin, Dept of Chest and Infectious Diseases, Zum Heckeshorn 33, 14109 Berlin, Germany. Fax: 49 3080022623. E-mail: haloheck@zedat.fu-berlin.de

Keywords: c-reactive protein, lower respiratory tract infection, procalcitonin, tuberculosis, white blood cell count

Received: June 26, 2002
Accepted January 23, 2003

The diagnostic significance of procalcitonin concentrations in lower respiratory tract infections and tuberculosis is not known. A prospective analysis was, therefore, performed in patients with acute exacerbation of chronic bronchitis (AECB), community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP) and tuberculosis and their procalcitonin levels compared with those of patients with noninfectious lung diseases (controls). In addition, standard inflammatory parameter data were collected.

A prospective clinical study was performed with four different groups of patients and a control group that consisted of patients with noninfectious lung diseases. A total of 129 patients were included: 25 with HAP, 26 CAP, 26 AECB, 27 tuberculosis, and 25 controls. C-reactive protein level, blood cell counts and procalcitonin concentration were evaluated on the first day after onset of clinical and inflammatory symptoms prior to treatment.

The median procalcitonin concentrations in HAP, CAP, AECB and tuberculosis were not elevated in relation to the cut-off level of 0.5 ng·mL–1. In the HAP group, in four of five patients who subsequently died, procalcitonin concentrations of >0.5 ng·mL–1 were found. In acute lower respiratory infections, such as HAP, CAP and AECB, significantly elevated levels were found in comparison to the control group, but below the usual cut-off level. No differences were observed between tuberculosis and the control group.

Relative to the current cut-off level of 0.5 ng·mL–1, procalcitonin concentration is not a useful parameter for diagnosis of lower respiratory tract infections. However, compared to the control group, there were significantly elevated levels in patients with hospital-acquired pneumonia, community-acquired pneumonia and acute exacerbation of chronic bronchitis below the current cut-off level, which should be further investigated.




This article has been cited by other articles:


Home page
ThoraxHome page
R Menendez, M Cavalcanti, S Reyes, J Mensa, R Martinez, M A Marcos, X Filella, M Niederman, and A Torres
Markers of treatment failure in hospitalised community acquired pneumonia
Thorax, May 1, 2008; 63(5): 447 - 452.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
S. Kruger, S. Ewig, R. Marre, J. Papassotiriou, K. Richter, H. von Baum, N. Suttorp, T. Welte, and on behalf of the CAPNETZ Study Group
Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes
Eur. Respir. J., February 1, 2008; 31(2): 349 - 355.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
J. Phua, E. S. C. Koay, D. Zhang, L. K. Tai, X. L. Boo, K. C. Lim, and T. K. Lim
Soluble triggering receptor expressed on myeloid cells-1 in acute respiratory infections
Eur. Respir. J., October 1, 2006; 28(4): 695 - 702.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
M. Masia, F. Gutierrez, C. Shum, S. Padilla, J. C. Navarro, E. Flores, and I. Hernandez
Usefulness of Procalcitonin Levels in Community-Acquired Pneumonia According to the Patients Outcome Research Team Pneumonia Severity Index
Chest, October 1, 2005; 128(4): 2223 - 2229.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
G. K. Schleicher, V. Herbert, A. Brink, S. Martin, R. Maraj, J. S. Galpin, and C. Feldman
Procalcitonin and C-reactive protein levels in HIV-positive subjects with tuberculosis and pneumonia
Eur. Respir. J., April 1, 2005; 25(4): 688 - 692.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the European Respiratory Society.